FGFR-2 (BEK) Expression in Diffuse Large B-Cell Lymphoma with Clinical Correlation
Loading...
Issue Date
2013
Authors
Benson, Jenna M. '13
Degree
MS in Biotechnology
Advisor
Nazeer, Tipu
Balachandran, Indra
Balachandran, Indra
Committee Members
Kim, Kelly-Ann
Wheeler, Elyse
Coleman, Arlixer
Wheeler, Elyse
Coleman, Arlixer
Journal Title
Journal ISSN
Volume Title
Abstract
In Western countries, diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma. This group of tumors is heterogeneous, exhibiting a variety of chromosomal abnormalities resulting in different subtypes of the disease and variable clinical outcomes for patients. There have been multiple studies conducted suggesting the ability to distinguish subtypes of DLBCL may lead to more effective therapy and eventually to better clinical outcomes. Fibroblast growth factor receptor 2 (FGFR-2) is part of a family of receptors that are involved in many cellular processes. The present study explored the significance of FGFR-2 expression for predicting clinical outcomes. In this study, 85 diffuse large B-cell lymphoma tissue samples were stained with rabbit polyclonal Bek which has anti-FGFR-2 specificity. The level of immunoreactivity with Bek was assessed and the results were correlated with clinical outcomes. Twenty-seven cases of DLBCL showed strong nuclear staining while 70 cases exhibited strong cytoplasmic staining. Both staining patterns were associated with early stage disease of DLBCL. The level of nuclear staining had a 48% correlation with early stage and 12% with advanced stage (p= 0.003). Cytoplasmic staining had a 97% correlation with early stage and 69% with advanced stage (p=0. 009). There was no significant correlation with rate of remission, recurrence, nodal status, age or overall survival. In conclusion, further research on subtyping of DLBCL is recommended in order to determine type-specific therapy protocols which will lead to a better prognosis for DLBCL patients.
Citation
Benson, Jenna M. "FGFR-2 (BEK) Expression in Diffuse Large B-Cell Lymphoma with Clinical Correlation." Albany College of Pharmacy and Health Sciences, New York, Proquest/UMI, 2013.
ACPHS Research Commons URI
Description
Click on the Resource Link to find this item in the ACPHS Library catalog